0.8626
price down icon5.03%   -0.0474
after-market Handel nachbörslich: .86 -0.0026 -0.30%
loading
Schlusskurs vom Vortag:
$0.91
Offen:
$0.94
24-Stunden-Volumen:
1.78M
Relative Volume:
2.25
Marktkapitalisierung:
$71.22M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-1.0269
EPS:
-0.84
Netto-Cashflow:
$-56.88M
1W Leistung:
-16.90%
1M Leistung:
-26.76%
6M Leistung:
-54.28%
1J Leistung:
-34.53%
1-Tages-Spanne:
Value
$0.8405
$0.94
1-Wochen-Bereich:
Value
$0.8405
$1.075
52-Wochen-Spanne:
Value
$0.8405
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Firmenname
Cytomx Therapeutics Inc
Name
Telefon
650.515.3185
Name
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
122
Name
Twitter
@cytomxinc
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
CTMX's Discussions on Twitter

Vergleichen Sie CTMX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
CTMX 0.8626 71.22M 101.21M -569.00K -56.88M -0.84
VRTX 467.12 119.83B 10.63B -479.80M -1.35B 13.33
REGN 762.38 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 567.35 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.83 24.08B 3.30B -501.07M 1.03B 11.54

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-05-28 Hochstufung Piper Sandler Neutral → Overweight
2024-05-09 Hochstufung Wedbush Neutral → Outperform
2024-05-06 Hochstufung Jefferies Hold → Buy
2024-04-22 Hochstufung JP Morgan Underweight → Neutral
2022-11-14 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-07-07 Herabstufung Jefferies Buy → Hold
2022-07-07 Herabstufung Mizuho Buy → Neutral
2022-07-07 Herabstufung Piper Sandler Overweight → Neutral
2022-07-07 Herabstufung Wedbush Outperform → Neutral
2022-06-24 Eingeleitet BMO Capital Markets Outperform
2022-01-18 Hochstufung Barclays Underweight → Overweight
2021-11-15 Eingeleitet BTIG Research Buy
2021-05-28 Herabstufung Barclays Equal Weight → Underweight
2021-03-29 Eingeleitet JP Morgan Overweight
2021-03-23 Hochstufung Jefferies Hold → Buy
2020-09-22 Herabstufung Guggenheim Buy → Neutral
2020-06-01 Herabstufung Jefferies Buy → Hold
2020-05-14 Bestätigt H.C. Wainwright Buy
2020-03-24 Hochstufung Wedbush Neutral → Outperform
2020-03-04 Eingeleitet Barclays Equal Weight
2019-11-20 Eingeleitet Guggenheim Buy
2019-11-11 Herabstufung Wedbush Outperform → Neutral
2019-06-13 Eingeleitet Mizuho Buy
2019-05-14 Eingeleitet Cantor Fitzgerald Overweight
2019-03-11 Eingeleitet Barclays Overweight
2018-11-26 Eingeleitet Piper Jaffray Overweight
2018-10-15 Eingeleitet Goldman Neutral
2018-09-13 Eingeleitet H.C. Wainwright Buy
2018-06-01 Eingeleitet SunTrust Buy
2018-01-05 Eingeleitet Citigroup Buy
2017-09-08 Eingeleitet Wedbush Outperform
2017-03-27 Eingeleitet H.C. Wainwright Buy
2017-03-02 Eingeleitet Instinet Buy
2017-01-03 Herabstufung Oppenheimer Outperform → Perform
2015-11-02 Eingeleitet Oppenheimer Outperform
Alle ansehen

Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten

pulisher
Nov 15, 2024

CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result - Yahoo Finance

Nov 06, 2024
pulisher
Nov 03, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St

Oct 26, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India

Oct 25, 2024
pulisher
Oct 17, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily

Oct 11, 2024
pulisher
Oct 06, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 06, 2024
pulisher
Sep 30, 2024

There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News

Sep 30, 2024
pulisher
Sep 29, 2024

Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News

Sep 26, 2024
pulisher
Sep 25, 2024

Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech

Sep 25, 2024
pulisher
Sep 24, 2024

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Reports Narrowed Losses - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN

Sep 23, 2024
pulisher
Sep 22, 2024

XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat

Sep 21, 2024
pulisher
Sep 21, 2024

Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World

Sep 21, 2024

Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Landau Jeffrey B
Chief Business Officer
Aug 20 '24
Sale
1.23
4,181
5,139
119,056
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Option Exercise
0.00
11,250
0
179,829
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Sale
1.23
4,181
5,139
175,648
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Option Exercise
0.00
11,250
0
134,978
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Sale
1.23
4,181
5,139
130,797
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Option Exercise
0.00
6,875
0
110,061
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Sale
1.23
1,984
2,439
108,077
McCarthy Sean A.
CEO
Aug 20 '24
Option Exercise
0.00
37,500
0
671,749
McCarthy Sean A.
CEO
Aug 20 '24
Sale
1.23
13,898
17,082
657,851
McCarthy Sean A.
CEO
Mar 26 '24
Option Exercise
1.57
109,768
172,874
634,249
$19.00
price up icon 4.27%
$76.98
price up icon 1.23%
$39.53
price up icon 7.03%
$359.21
price down icon 0.88%
$187.76
price down icon 0.58%
$101.83
price up icon 2.00%
Kapitalisierung:     |  Volumen (24h):